Trial Profile
A Randomized Comparison of Recanalisation With Implantation of Cypher Sirolimus Eluting Coronary Stents and Medical Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Dec 2019
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Angina pectoris; Coronary artery disease; Ischaemia; Myocardial infarction
- Focus Therapeutic Use
- Acronyms REVASC
- 03 Nov 2017 Status changed from recruiting to completed.
- 02 Mar 2017 New trial record